Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123


Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.


Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC.

Expert Rev Vaccines. 2006 Jun;5(3):347-63. Review.


Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Zolla-Pazner S, Cardozo T.

Nat Rev Immunol. 2010 Jul;10(7):527-35. doi: 10.1038/nri2801. Review.


Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6. doi: 10.1073/pnas.1103012108. Epub 2011 Jun 20.


Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.


GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.


HIV. The modern era of HIV-1 vaccine development.

Mascola JR.

Science. 2015 Jul 10;349(6244):139-40. doi: 10.1126/science.aac7800. No abstract available.


HIV vaccine design and the neutralizing antibody problem.

Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT.

Nat Immunol. 2004 Mar;5(3):233-6. No abstract available.


Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.

Zipeto D, Matucci A, Ripamonti C, Scarlatti G, Rossolillo P, Turci M, Sartoris S, Tridente G, Bertazzoni U.

Microbes Infect. 2006 May;8(6):1424-33. Epub 2006 Apr 18.


Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.


Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.


[VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].

Vzorov AN, Compans RW.

Mol Biol (Mosk). 2016 May-Jun;50(3):406-15. doi: 10.7868/S0026898416030113. Review. Russian.


HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.

Verkoczy L, Kelsoe G, Haynes BF.

PLoS Pathog. 2014 May 22;10(5):e1004073. doi: 10.1371/journal.ppat.1004073. eCollection 2014 May. No abstract available.


DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.


HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.


Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.

Cheeseman HM, Olejniczak NJ, Rogers PM, Evans AB, King DF, Ziprin P, Liao HX, Haynes BF, Shattock RJ.

J Virol. 2016 Dec 16;91(1). pii: e01762-16. Print 2017 Jan 1.

Supplemental Content

Support Center